Abstracts Archive - Page 2133 of 2425 - ACR Meeting Abstracts

Abstract Number: 1777 • 2013 ACR/ARHP Annual Meeting
Antibodies Against TIF1-Gamma In Cancer Associated Myositis May Precede Cancer Symptoms and Persist After Cancer Removal
Ingrid E. Lundberg¹, Lara Dani², Maryam Dastmalchi², Maria Angeles Martinez³, Moises Labrador-Horrillo⁴ and Albert Selva O'Callaghan⁴, ¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Sant Pau Hospital, Barcelona, Spain, ⁴Vall d'Hebron General Hospital, Barcelona, Spain
Background/Purpose: Antibodies against TIF1-gamma have been detected in patients with cancer associated myositis (CAM) but it is not known whether the antibodies precede the diagnosis…
Abstract Number: 1778 • 2013 ACR/ARHP Annual Meeting
Physical Interactions Between Histidyl-tRNA Synthetase and Endogenous/Exogenous Alarmins Enhance Immunogenicity In a Model Of Antigen-Induced Myositis
Irina Fernandez¹, Lisa Harlow², William Ridgway³ and Dana P. Ascherman⁴, ¹Rheumatology, University of Miami, Miami, FL, ²Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ³Immunology, Allergy and Rheumatology, University of Cincinnati, Cincinnati, OH, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Objective: To assess the biological interplay between histidyl-tRNA synthetase (HRS) and different endogenous/exogenous ligands capable of generating signals through MyD88-dependent receptor systems in idiopathic inflammatory…
Abstract Number: 1779 • 2013 ACR/ARHP Annual Meeting
A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis
Li Alemo Munters^1,2, Ingela M. Loell³, Joan Raouf⁴, Maryam Dastmalchi³, Eva Lindroos⁵, Christina Ottosson⁶, Yi-Wen Chen⁷, Annemarie F van Delden⁸, Mona Esbjörnsson⁹, Marina Korotkova¹⁰, Helene Alexanderson¹¹, Kanneboyina Nagaraju¹² and Ingrid E. Lundberg¹³, ¹Department of Medicine, Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Physiotherapy, Rheumatology Unit, Karolinska University Hospital in Solna, Stockholm, Sweden, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁷Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, ⁸Department of Medicine,, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁹Department of Physiology, Karolinska Institutet, Huddinge, Sweden, ¹⁰Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ¹¹Department of Neurobiology, Care Science and Society, Division of Physiotherapy, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, ¹²Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ¹³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: This pilot study is a hypothesis-driven exploratory part of a larger randomized controlled trial evaluating effects of a supervised 12-week endurance exercise program (EG)…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 1781 • 2013 ACR/ARHP Annual Meeting
Clinical Variation In Children With Mutations In MEFV
Karyl Barron¹, Amanda K. Ombrello², Ivona Aksentijevich³, Anne Jones³ and Daniel L. Kastner³, ¹Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²National Human Genome Research Institute,National Institute of Health, Bethesda, MD, ³Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: As a referral clinic for children with periodic fevers, we see a wide variety of clinical presentations. While genetic testing is usually helpful in…
Abstract Number: 1782 • 2013 ACR/ARHP Annual Meeting
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperatures (CANDLE): Clinical Characterization and Initial Response To Janus Kinase Inhibition With Baricitinib
Gina A. Montealegre Sanchez¹, Adam L. Reinhardt², Paul Brogan³, Yackov Berkun⁴, Diane Brown⁵, Peter Chira⁶, Ling Gao⁷, Dawn C. Chapelle¹, Nicole Plass¹, Hanna Kim¹, Michael Davis⁸, Adriana Almeida de Jesus⁸, Yin Liu¹, Yan Huang¹, Colleen Hadigan⁹, Theo Heller¹⁰, Zlotogorski Zlotogorski¹¹, John J. O'Shea¹², Chyi-chia Lee¹³, Suvimol C. Hill¹⁴, Kristina Rother¹⁵, Massimo Gadina¹⁶ and Raphaela T. Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁴Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, ⁵Division Of Rheumatology MS #60, Children's Hospital Los Angeles, Los Angeles, CA, ⁶Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ⁷Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁹National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, ¹⁰National Institute of Diabetes and Digestive Kidney Diseases, NIH, Bethesda, MD, ¹¹Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Jerusalem, Israel, ¹²NIAMS, Bethesda, MD, ¹³National Cancer Institute, National Institutes of Health, Bethesda, MD, ¹⁴Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, ¹⁵Pediatric Diabetes & Metabolism, National Institute of Diabetes and Digestive Kidney Diseases, NIH, Bethesda, MD, ¹⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: CANDLE, a novel autoinflammatory syndrome presents with attacks of fever, annular cutaneous plaques, persistent periorbital edema, arthritis, lymphopenia and lipodystrophy since early childhood. CANDLE…
Abstract Number: 1783 • 2013 ACR/ARHP Annual Meeting
Canakinumab Treatment In Active Hyper-IgD With Periodic Fever Syndrome
Juan Ignacio Aróstegui¹, Inmaculada Calvo², Jordi Anton³, Angel Robles⁴, Jordi Yagüe¹, Ruth Viana⁵, Lillian Tseng⁶ and Ken Abrams⁶, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital La Fe, Valencia, Spain, ³Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁴Hospital La Paz, Madrid, Spain, ⁵Medical Department, Novartis Farmacéutica, S.A., Barcelona, Spain, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Hyper-IgD with periodic fever syndrome (HIDS) is a recessively inherited autoinflammatory disease due to biallelic MVK mutations. It is characterized by 4-6 days-long acute…
Abstract Number: 1784 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of First Line Use Of Recombinant IL-1RA Treatment In Steroid naïve Systemic Juvenile Idiopathic Arthritis: Results Of a Prospective Cohort Study
S.J. Vastert¹, Wilco de Jager², Bo Jan Noordman², Dirk Holzinger³, Wietse Kuis⁴, Berent J. Prakken² and Nico M. Wulffraat⁵, ¹Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Institute of Immunology, University Muenster, Muenster, Germany, ⁴Pediatric immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵UMC Utrecht, Utrecht, Netherlands
Background/Purpose: To perform a prospective cohort study with recombinant IL-1RA (Anakinra, rIL-1RA) as first-line therapy in newly onset sJIA. Methods: Patients fulfilled the ILAR criteria…
Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Jon M. Burnham¹, Babette S. Zemel¹, David C. Lee², Tony M. Keaveny³ and Mary Beth Leonard¹, ¹Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²O.N. Diagnostics, LLC, Berkeley, CA, ³Founder and Chief Science Officer, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…
Abstract Number: 1786 • 2013 ACR/ARHP Annual Meeting
91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies
Walter P. Maksymowych¹, Dirkjan van Schaardenburg², Désirée van der Heijde³, Robert Landewé⁴, Gilles Boire⁵, Maarten Boers⁶, Vivian P. Bykerk⁷, Edward C. Keystone⁸, Katherine A. Siminovitch⁹, Mairead Murphy¹⁰ and Anthony Marotta¹¹, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Augurex Life Sciences Corp., North Vancouver, BC, Canada, ¹¹Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Current serological markers such as RF and ACPA are useful for early diagnosis and perhaps for screening people at risk, but there remains a…
Abstract Number: 1787 • 2013 ACR/ARHP Annual Meeting
Does Age At Disease Onset Influence Disease Activity and Function In Rheumatoid Arthritis Patients? Results From The Ontario Best Practices Research Initiative (OBRI) Registry
Thanu Nadarajah¹, Binu Jacob², Pooneh Akhavan³, Bindee Kuriya⁴, Edward C. Keystone⁵ and Claire Bombardier⁶, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The population of elderly individuals with rheumatoid arthritis (RA) is increasing. The aim of this study was to assess whether age at disease onset…
Abstract Number: 1748 • 2013 ACR/ARHP Annual Meeting
Autoantibodies To RuvBL1 and RuvBL2: A Novel Systemic Sclerosis-Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement
Kenzo Kaji¹, Noreen Fertig², Thomas A. Medsger Jr.³, Takashi Sathoh⁴, Kana Hoshino⁴, Yasuhito Hamaguchi¹, Minoru Hasegawa⁵, Mary Lucas⁶, Andrew Schnure⁶, Fumihide Ogawa⁷, Shinichi Sato⁸, Kazuhiko Takehara⁹, Manabu Fujimoto⁵ and Masataka Kuwana⁴, ¹Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ²University of Pittsburgh, Pittsburgh, PA, ³Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁶Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan, ⁹Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Detection of serum autoantibodies is useful in diagnosis, disease subgrouping, and prediction of subsequent organ involvement and prognosis in patients with systemic sclerosis (SSc).…
Abstract Number: 1749 • 2013 ACR/ARHP Annual Meeting
Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction
Priya Prakash¹, Dhaval Kolte¹, Sahil Khera¹, Jagadish Khanagavi¹, Marjan Mujib², Chandrasekar Palaniswamy³, Farrah Gutwein⁴, Sachin Sule¹, Wilbert S. Aronow³, William H. Frishman³ and Julia Ash⁴, ¹Medicine, New York Medical College, Valhalla, NY, ²Internal Medicine, New York Medical College, Valhalla, NY, ³Cardiology, New York Medical College, Valhalla, NY, ⁴Rheumatology, New York Medical College, Valhalla, NY
Background/Purpose: , Systemic Sclerosis (SSc) is associated with an increased risk of cardiovascular diseases, including acute myocardial infarction (AMI). However, whether SSc influences treatment choice and…
Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Francisco Ortiz-Sanjuan¹, Vanesa Calvo-Río², Ricardo Blanco³, Emma Beltrán⁴, Juan Sánchez-Bursón⁵, Marina Mesquida⁶, Alfredo M. Adan⁶, M Hernandez Grafella⁷, E Valls Pascual⁸, L Martínez-Costa⁹, Agustí Sellas-Fernàndez¹⁰, Miguel Cordero-Coma¹¹, Manuel Diaz-llopis¹², David Salom¹², Jl García Serrano¹³, Norberto Ortego¹³, JM Herreras¹⁴, Alejandro Fonollosa¹⁵, A Aparicio¹⁶, O Maíz¹⁷, A Blanco¹⁸, I Torre¹⁹, Cruz Fernández-Espartero²⁰, V Jovani²¹, D Peitado-Lopez²², Esperanza Pato²³, J Cruz²⁴, J. Carlos Fernandez-Cid²⁵, E. Aurrecoechea²⁶, M García²⁷, M Caracuel²⁸, Carlos Montilla²⁹, A Atanes³⁰, F Francisco³¹, S Insua³², S González-Suárez³³, A Sánchez-Andrade³⁴, F Gamero³⁵, Luis Linares³⁶, F Romero-Bueno³⁷, AJ García González³⁸, Raquel Almodovar³⁹, E Minguez⁴⁰, C Carrasco Cubero⁴¹, Alejandro Olive Marques⁴², J Vázquez⁴³, O Ruiz Moreno⁴⁴, F Jimenez-Zorzo⁴⁴, J Manero⁴⁴, Javier Loricera¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital de Valme. Sevilla, Sevilla, Spain, ⁶Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Peset Valencia, Valencia, Spain, ⁹Ophthalmology, Hospital Peset Valencia, Valencia, Spain, ¹⁰Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, ¹¹Departament of Ophthalmology, Hospital de León, León, Spain, ¹²Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ¹³Hospital San Cecilio. Granada, Granada, Spain, ¹⁴Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ¹⁵Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain, ¹⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ¹⁷Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁸Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁹Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, ²⁰Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, ²¹Rheumatology., Hospital General de Alicante., Alicante, Spain, ²²Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ²³Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, ²⁴Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁵Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁶Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁷Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, ²⁸Rheumatology., Hospital de Córdoba., Córdoba, Spain, ²⁹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ³⁰Rheumatology., HUCA La Coruña., A Coruña, Spain, ³¹Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, ³²Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ³³Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ³⁴Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, ³⁵Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ³⁷Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, ³⁸Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, ³⁹Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, ⁴⁰Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴¹Rheumatology., Hospital de Mérida, Mérida, Spain, ⁴²Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, ⁴³Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, ⁴⁴Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain
Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…
Abstract Number: 1751 • 2013 ACR/ARHP Annual Meeting
Ethnicity-Related Differences In Behçet’s Disease In a French Multiethnic Country
David Saadoun¹, Mathieu Resche Rigon², Bertrand Wechsler³, Du Le Thi Huong⁴, Jean-Charles Piette¹ and Patrice Cacoub⁵, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: It has been suggested that Behçet’s disease (BD) varies in its phenotypic expression in different ethnies and in different countries indicating that both environmental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].